StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA – Free Report) in a research report released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Cara Therapeutics Stock Performance
NASDAQ CARA opened at $0.26 on Friday. The company has a market cap of $14.00 million, a P/E ratio of -0.11 and a beta of 0.70. The business’s 50 day moving average price is $0.31 and its 200-day moving average price is $0.48. Cara Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $1.65.
Cara Therapeutics (NASDAQ:CARA – Get Free Report) last announced its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The firm had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.26 million. As a group, equities analysts predict that Cara Therapeutics will post -1.24 EPS for the current year.
Institutional Inflows and Outflows
About Cara Therapeutics
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Read More
- Five stocks we like better than Cara Therapeutics
- What is Short Interest? How to Use It
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- EV Stocks and How to Profit from Them
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- What Are Some of the Best Large-Cap Stocks to Buy?
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.